Molecular and cellular mechanisms of learning disabilities: A focus on NF1

Annual Review of Neuroscience

Volumn 33, Issue , 2010, Pages 221-243

  Shilyansky, C ^a   Lee, Y S ^a   Silva, A J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ADHD; animal model; GABA; LTP; neurodevelopmental disorder; Ras

Indexed keywords

MEVINOLIN; NEUROFIBROMIN;

4 AMINOBUTYRIC ACID RELEASE; BEHAVIOR; COGNITION; CYTOLOGY; GENE EXPRESSION; HUMAN; IDIOPATHIC DISEASE; INTERNEURON; LEARNING DISORDER; MOLECULAR MECHANICS; NEUROFIBROMATOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LEARNING DISORDERS; NEUROFIBROMATOSIS 1; RAS PROTEINS;

EID: 77953933733     PISSN: 0147006X     EISSN: 15454126     Source Type: Book Series    
DOI: 10.1146/annurev-neuro-060909-153215     Document Type: Review

References (108)

1. Aarde SM, Jentsch JD. 2006. Haploinsufficiency of the arginine-vasopressin gene is associated with poor spatial working memory performance in rats. Horm. Behav. 49:501-508
2. Altarac M, Saroha E. 2007. Lifetime prevalence of learning disability among US children. Pediatrics 119(Suppl. 1):S77-83
3. Araki T, Chan G, Newbigging S, Morikawa L, Bronson RT, Neel BG. 2009. Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation. Proc. Natl. Acad. Sci. USA 106:4736-4741
4. Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, et al. 2004. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat. Med. 10:849-857
5. Bannerman DM, Niewoehner B, Lyon L, Romberg C, Schmitt WB, et al. 2008. NMDA receptor subunit NR2A is required for rapidly acquired spatial working memory but not incremental spatial reference memory. J. Neurosci. 28:3623-3630
6. Barker D, Wright E, Nguyen K, CannonL,Fain P, et al. 1987. Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science 236:1100-1102
7. Barton B, North K. 2004. Social skills of children with neurofibromatosis type 1. Dev. Med. Child Neurol. 46:553-563
8. Bernards A, Settleman J. 2004. GAP control: regulating the regulators of small GTPases. Trends Cell Biol. 14:377-385
9. Bernards A, Settleman J. 2005. GAPs in growth factor signaling. Growth Factors 23:143-149
10. Bernards A, Snijders AJ, HanniganGE, Murthy AE,Gusella JF. 1993. Mouse neurofibromatosis type 1 cDNA sequence reveals high degree of conservation of both coding and noncoding mRNA segments. Hum. Mol. Genet. 2:645-650
11. Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, et al. 2009. A pilot open label, single dose trial of fenobam in adults with Fragile X syndrome. J. Med. Genet. 46:266-271
12. Boguski MS, McCormick F. 1993. Proteins regulating Ras and its relatives. Nature 366:643-654
13. BremsH, ChmaraM, SahbatouM,Denayer E, Taniguchi K, et al. 2007. Germline loss-of-functionmutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat. Genet. 39:1120-1126
14. Cannon TD, Glahn DC, Kim J, Van Erp TG, Karlsgodt K, et al. 2005. Dorsolateral prefrontal cortex activity during maintenance and manipulation of information in working memory in patients with schizophrenia. Arch. Gen. Psychiatry 62:1071-1080
15. Chadman KK, Yang M, Crawley JN. 2009. Criteria for validating mouse models of psychiatric diseases. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B:1-11
16. Cichowski K, Santiago S, Jardim M, Johnson BW, Jacks T. 2003. Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes Dev. 17:449-454
17. Compte A, Brunel N, Goldman-Rakic PS, Wang XJ. 2000. Synaptic mechanisms and network dynamics underlying spatial working memory in a cortical network model. Cereb. Cortex 10:910-923
18. Constantinidis C, Goldman-Rakic PS. 2002. Correlated discharges among putative pyramidal neurons and interneurons in the primate prefrontal cortex. J. Neurophysiol. 88:3487-3497
19. Constantinidis C, Williams GV, Goldman-Rakic PS. 2002. A role for inhibition in shaping the temporal flow of information in prefrontal cortex. Nat. Neurosci. 5:175-180
20. Costa R, Elgersma Y, Silva AJ. 2003. Modeling cognitive disorders: from genes to therapies. In Genetics and Genomics of Neurobehavioral Disorders, ed. G Fisch, pp. 39-68. Totowa, NJ: Humana Press
21. Costa RM, Federov NB, Kogan JH, Murphy GG, Stern J, et al. 2002. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 415:526-530
22. Costa RM, Yang T, Huynh DP, Pulst SM, Viskochil DH, et al. 2001. Learning deficits, but normal development and tumor predisposition, in mice lacking exon 23a of Nf1. Nat. Genet. 27:399-405
23. Cui Y, Costa RM, Murphy GG, Elgersma Y, Zhu Y, et al. 2008. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 135:549-560
24. Demeter E, Sarter M, Lustig C. 2008. Rats and humans paying attention: cross-species task development for translational research. Neuropsychology 22:787-799
25. Denayer E, Ahmed T, Brems H, Van Woerden G, Borgesius NZ, et al. 2008. Spred1 is required for synaptic plasticity and hippocampus-dependent learning. J. Neurosci. 28:14443-14449
26. Dilts CV, Carey JC, Kircher JC, Hoffman RO, Creel D, et al. 1996. Children and adolescents with neurofibromatosis 1: a behavioral phenotype. J. Dev. Behav. Pediatr. 17:229-239
27. Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, et al. 2007. Correction of Fragile X syndrome in mice. Neuron 56:955-962
28. Easton DF, Ponder MA, Huson SM, Ponder BA. 1993. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am. J. Hum. Genet. 53:305-313
29. Ehninger D, Li W, Fox K, Stryker MP, Silva AJ. 2008. Reversing neurodevelopmental disorders in adults. Neuron 60:950-960
30. Fagiolini M, Hensch TK. 2000. Inhibitory threshold for critical-period activation in primary visual cortex. Nature 404:183-186
31. Fellous JM, Sejnowski TJ. 2003. Regulation of persistent activity by background inhibition in an in vitromodel of a cortical microcircuit. Cereb. Cortex 13:1232-1241
32. Fossella JA, Casey BJ. 2006. Genes, brain, and behavior: bridging disciplines. Cogn. Affect. Behav. Neurosci. 6:1-8
33. Fountain JW,Wallace MR, Bruce MA, Seizinger BR, Menon AG, et al. 1989. Physical mapping of a translocation breakpoint in neurofibromatosis. Science 244:1085-1087
34. Friedman JM. 1999. Epidemiology of neurofibromatosis type 1. Am. J. Med. Genet. 89:1-6
35. Guo HF, Tong J, Hannan F, Luo L, Zhong Y. 2000. A neurofibromatosis-1- regulated pathway is required for learning in Drosophila. Nature 403:895-898
36. Gutmann DH, Geist RT, Wright DE, Snider WD. 1995. Expression of the neurofibromatosis 1 (NF1) isoforms in developing and adult rat tissues. Cell Growth Differ. 6:315-323
37. Hagerman RJ, Berry-Kravis E, KaufmannWE, OnoMY, Tartaglia N, et al. 2009. Advances in the treatment of Fragile X syndrome. Pediatrics 123:378-390
38. Hajra A, Martin-Gallardo A, Tarle SA, Freedman M, Wilson-Gunn S, et al. 1994. DNA sequences in the promoter region of the NF1 gene are highly conserved between human and mouse. Genomics 21:649-652
39. Hannan F, Ho I, Tong JJ, Zhu Y, Nurnberg P, Zhong Y. 2006. Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras. Hum. Mol. Genet. 15:1087-1098
40. Hasenstaub A, Shu Y, Haider B, Kraushaar U, Duque A, McCormick DA. 2005. Inhibitory postsynaptic potentials carry synchronized frequency information in active cortical networks. Neuron 47:423-435
41. Hawes JJ, Tuskan RG, Reilly KM. 2007. Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies. Neurogenetics 8:121-130
42. Hensch TK. 2004. Critical period regulation. Annu. Rev. Neurosci. 27:549-579
43. Hensch TK. 2005. Critical period plasticity in local cortical circuits. Nat. Rev. Neurosci. 6:877-888
44. Hofman KJ, Harris EL, Bryan RN, Denckla MB. 1994. Neurofibromatosis type 1: the cognitive phenotype. J. Pediatr. 124:S1-8
45. Husi H, Ward MA, Choudhary JS, Blackstock WP, Grant SG. 2000. Proteomic analysis of NMDA receptoradhesion protein signaling complexes. Nat. Neurosci. 3:661-669
46. Hyman SL, Shores A, North KN. 2005. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 65:1037-1044
47. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. 1994. Tumor predisposition in mice heterozygous for a targeted mutation in Nf1. Nat. Genet. 7:353-361
48. Jentsch JD, Aarde SM,SeuE. 2009. Effects of atomoxetine andmethylphenidate on performance of a lateralized reaction time task in rats. Psychopharmacology 202:497-504
49. Kayl AE, Moore BD, 3rd. 2000. Behavioral phenotype of neurofibromatosis, type 1. Ment. Retard. Dev. Disabil. Res. Rev. 6:117-124
50. Kelly DP. 2004. Neurodevelopmental dysfunction in the school-aged child. In Nelson Textbook of Pediatrics, ed. RE Behrman, RM Kliegman, HB Jenson, pp. 110-112 Philadelphia: Saunders. 17th ed.
51. Knudsen EI. 2004. Sensitive periods in the development of the brain and behavior. J. Cogn. Neurosci. 16:1412-1425
52. Koos T, Tepper JM. 1999. Inhibitory control of neostriatal projection neurons by GABAergic interneurons. Nat. Neurosci. 2:467-472
53. Koth CW, Cutting LE, DencklaMB. 2000. The association of neurofibromatosis type 1 and attention deficit hyperactivity disorder. Child Neuropsychol. 6:185-194
54. Krab LC, Aarsen FK, de Goede-Bolder A, Catsman-Berrevoets CE, Arts WF, et al. 2008a. Impact of neurofibromatosis type 1 on school performance. J. Child Neurol. 23:1002-1010
55. Krab LC, de Goede-Bolder A, Aarsen FK, Pluijm SM, Bouman MJ, et al. 2008b. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA 300:287-294
56. Kronenberger WG, Dunn DW. 2003. Learning disorders. Neurol. Clin. 21:941-952
57. Lagae L. 2008. Learning disabilities: definitions, epidemiology, diagnosis, and intervention strategies. Pediatr. Clin. North Am. 55:1259-68, vii
58. Leach RJ, Thayer MJ, Schafer AJ, Fournier RE. 1989. Physical mapping of human chromosome 17 using fragment-containing microcell hybrids. Genomics 5:167-176
59. Ledbetter DH, Rich DC, O'Connell P, Leppert M, Carey JC. 1989. Precise localization of NF1 to 17q11.2 by balanced translocation. Am. J. Hum. Genet. 44:20-24
60. Lee DA, Portnoy S, Hill P, Gillberg C, Patton MA. 2005. Psychological profile of children with Noonan syndrome. Dev. Med. Child Neurol. 47:35-38
61. Lee YS, Silva AJ. 2009. The molecular and cellular biology of enhanced cognition. Nat. Rev. 10:126-140
62. Leondaritis G, Petrikkos L, Mangoura D. 2009. Regulation of the Ras-GTPase activating protein neurofibromin by C-tail phosphorylation: implications for protein kinase C/Ras/extracellular signal-regulated kinase 1/2 pathway signaling and neuronal differentiation. J. Neurochem. 109(2):573-583
63. Li W, Cui Y, Kushner SA, Brown RA, Jentsch JD, et al. 2005. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr. Biol. 15:1961-1967
64. Li Y, O'Connell P, Breidenbach HH, Cawthon R, Stevens J, et al. 1995. Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics 25:9-18
65. Luikart BW, Zhang W, Wayman GA, Kwon CH,Westbrook GL, Parada LF. 2008. Neurotrophin-dependent dendritic filopodial motility: a convergence on PI3K signaling. J. Neurosci. 28:7006-7012
66. Lush ME, Li Y, Kwon CH, Chen J, Parada LF. 2008. Neurofibromin is required for barrel formation in the mouse somatosensory cortex. J. Neurosci. 28:1580-1587
67. Lynch TM, Gutmann DH. 2002. Neurofibromatosis 1. Neurol. Clin. 20:841-865
68. Marchuk DA, Saulino AM, Tavakkol R, Swaroop M, Wallace MR, et al. 1991. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics 11:931-940
69. Martin SJ, Grimwood PD,Morris RG. 2000. Synaptic plasticity and memory: an evaluation of the hypothesis. Annu. Rev. Neurosci. 23:649-711
70. Martin SJ,Morris RG. 2002. New life in an old idea: the synaptic plasticity and memory hypothesis revisited. Hippocampus 12:609-636
71. Mautner VF, Kluwe L, Thakker SD, Leark RA. 2002. Treatment of ADHD in neurofibromatosis type 1. Dev. Med. Child Neurol. 44:164-170
72. Money J, Kalus ME Jr. 1979. Noonan's syndrome. IQ and specific disabilities. Am. J. Dis. Child. 133:846-850
73. Morris RG, Garrud P, Rawlins JN, O'Keefe J. 1982. Place navigation impaired in rats with hippocampal lesions. Nature 297:681-683
74. Moser EI, Krobert KA, Moser MB, Morris RG. 1998. Impaired spatial learning after saturation of long-term potentiation. Science 281:2038-2042
75. Noonan JA. 1994. Noonan syndrome. An update and review for the primary pediatrician. Clin. Pediatr. 33:548-555
76. North K. 2000. Neurofibromatosis type 1. Am. J. Med. Genet. 97:119-127
77. North KN, Riccardi V, Samango-Sprouse C, Ferner R,Moore B, et al. 1997. Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from theNF1 CognitiveDisorders Task Force. Neurology 48:1121-1127
78. Palumbo D, Lynch PA. 2006. Psychological testing in adolescent medicine. Adolesc. Med. Clin. 17:147-164
79. Pasmant E, Sabbagh A, Hanna N, Masliah-Planchon J, Jolly E, et al. 2009. SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. J. Med. Genet. 46:425-430
80. Patapoutian A, Reichardt LF. 2001. Trk receptors: mediators of neurotrophin action. Curr. Opin. Neurobiol. 11:272-280
81. Ramus F. 2003. Developmental dyslexia: specific phonological deficit or general sensorimotor dysfunction? Curr. Opin. Neurobiol. 13:212-218
82. Rao SG, Williams GV, Goldman-Rakic PS. 2000. Destruction and creation of spatial tuning by disinhibition: GABAA blockade of prefrontal cortical neurons engaged by working memory. J. Neurosci. 20:485-494
83. Richter-Levin G, Canevari L, Bliss TV. 1995. Long-term potentiation and glutamate release in the dentate gyrus: links to spatial learning. Behav. Brain Res. 66:37-40
84. Robbins TW. 2002. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology 163:362-380
85. Rosser TL, Packer RJ. 2003. Neurocognitive dysfunction in children with neurofibromatosis type 1. Curr. Neurol. Neurosci. Rep. 3:129-136
86. Rowbotham I, Pit-ten Cate IM, Sonuga-Barke EJ,Huijbregts SC. 2009. Cognitive control in adolescents with neurofibromatosis type 1. Neuropsychology 23:50-60
87. Sabbagh A, Pasmant E, Laurendeau I, Parfait B, Barbarot S, et al. 2009. Unraveling the genetic basis of variable clinical expression in neurofibromatosis 1. Hum. Mol. Genet. 18:2779-2790
88. Sanchez-Vives MV, McCormick DA. 2000. Cellular and network mechanisms of rhythmic recurrent activity in neocortex. Nat. Neurosci. 3:1027-1034
89. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Faryniarz AG, et al. 1987. Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell 49:589-594
90. Shen MH, Harper PS, Upadhyaya M. 1996. Molecular genetics of neurofibromatosis type 1 (NF1). J. Med. Genet. 33:2-17
91. Silva AJ, Frankland PW, Marowitz Z, Friedman E, Laszlo GS, et al. 1997. A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat. Genet. 15:281-284
92. Silva AJ, Paylor R, Wehner JM, Tonegawa S. 1992a. Impaired spatial learning in alpha-calcium-calmodulin kinase II mutant mice. Science 257:206-211
93. Silva AJ, Stevens CF, Tonegawa S, Wang Y. 1992b. Deficient hippocampal long-term potentiation in alphacalcium- calmodulin kinase II mutant mice. Science 257:201-206
94. Spurlock G, Bennett E, Chuzhanova N, Thomas N, Jim HP, et al. 2009. SPRED1 mutations (Legius syndrome): another clinically useful genotype for dissecting the neurofibromatosis type 1 phenotype. J. Med. Genet. 46:431-437
95. Tartaglia M, Gelb BD. 2005. Noonan syndrome and related disorders: genetics and pathogenesis. Annu. Rev. Genomics Hum. Genet. 6:45-68
96. Tepper JM, Wilson CJ, Koos T. 2008. Feedforward and feedback inhibition in neostriatal GABAergic spiny neurons. Brain Res. Rev. 58:272-281
97. Thomson SA, Fishbein L, Wallace MR. 2002. NF1 mutations and molecular testing. J. Child Neurol. 17:555- 61; discussion 71-72, 646-651
98. Tong J, Hannan F,Zhu Y, Bernards A, ZhongY. 2002. Neurofibromin regulatesGprotein-stimulated adenylyl cyclase activity. Nat. Neurosci. 5:95-96
99. Viskochil D, Buchberg AM, XuG,Cawthon RM, Stevens J, et al. 1990. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62:187-192
100. Vogel KS, Brannan CI, Jenkins NA, Copeland NG, Parada LF. 1995. Loss of neurofibromin results in neurotrophin-independent survival of embryonic sensory and sympathetic neurons. Cell 82:733-742
101. Wallace MR,Marchuk DA, Andersen LB, Letcher R, Odeh HM, et al. 1990. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249:181-186
102. Ward BA, Gutmann DH. 2005. Neurofibromatosis 1: from lab bench to clinic. Pediatr. Neurol. 32:221-228
103. Weeber EJ, Sweatt JD. 2002. Molecular neurobiology of human cognition. Neuron 33:845-848
104. Weiss B, Bollag G, Shannon K. 1999. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am. J. Med. Genet. 89:14-22
105. Williams JA, Su HS, Bernards A, Field J, Sehgal A. 2001. A circadian output in Drosophila mediated by neurofibromatosis-1 and Ras/MAPK. Science 293:2251-2256
106. Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. 2009. Neurofibromatosis type 1 revisited. Pediatrics 123:124-133
107. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. 2002. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296:920-922
108. Zhu Y, Romero MI, Ghosh P, Ye Z, Charnay P, et al. 2001. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev. 15:859-876